Share on StockTwits

Aegis hoisted their price objective on shares of China Cord Blood (NYSE:CO) from $5.00 to $7.00 in a research note issued on Tuesday, AR Network reports. The firm currently has a “buy” rating on the stock. Aegis’ price objective would indicate a potential upside of 66.67% from the stock’s previous close.

Shares of China Cord Blood (NYSE:CO) traded down 2.88% during mid-day trading on Tuesday, hitting $4.05. 83,810 shares of the company’s stock traded hands. China Cord Blood has a one year low of $2.67 and a one year high of $4.60. The stock has a 50-day moving average of $3.95 and a 200-day moving average of $3.95. The company has a market cap of $295.7 million and a price-to-earnings ratio of 17.90.

China Cord Blood (NYSE:CO) last released its earnings data on Monday, February 24th. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.06 by $0.01. The company had revenue of $24.90 million for the quarter, compared to the consensus estimate of $24.22 million. Analysts expect that China Cord Blood will post $0.25 EPS for the current fiscal year.

China Cord Blood Corporation (NYSE:CO), formerly Pantheon China Acquisition Corp.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.